Omalizumab Linked to Lower Heart Disease Risk

Patients treated with omalizumab show a reduced risk of cardiovascular disease compared to those using other therapies.

Updated on Oct. 26, 2026 in Allergies

Isometric editorial illustration showing a medical vial and a stylized heart model, representing research into cardiovascular health outcomes. — A retrospective study published in the United States finds that patients treated with omalizumab exhibit a lower risk of cardiovascular disease. AI Illustration. Upload story photo >

Live Poll

Do you prioritize cardiovascular risk profiles when choosing medications for chronic inflammatory conditions?

A new retrospective cohort study indicates that patients with chronic spontaneous urticaria have a lower risk of cardiovascular disease when treated with omalizumab. The drug demonstrates a superior safety profile for cardiac health relative to oral corticosteroids or second-generation antihistamines.

Why it matters

Identifying treatment options that minimize long-term cardiac risks is essential for managing chronic urticaria. These findings provide clinicians with comparative evidence to help prioritize therapies based on secondary health outcomes.

Within a 3-year period, 3.55% of omalizumab-treated patients developed cardiovascular disease, compared to 8.06% of those treated with oral corticosteroids. The study cohort had a mean age of 43 years and consisted of approximately 77% women.

The players

TriNetX

This global health research network provides the clinical data infrastructure used to analyze large-scale patient outcomes.

The details

Researchers analyzed data from the US Collaborative Network of TriNetX, comparing patient outcomes across three common urticaria treatments. Eligible participants included individuals with at least two documented urticaria diagnostic codes recorded at least six weeks apart.

October 21, 2026: Study results published online as a Letter.

Health Landscape

This study leverages data from the US Collaborative Network of TriNetX to identify long-term treatment risks in large patient populations. The research highlights a shift toward using massive electronic health record databases to evaluate secondary outcomes for chronic condition therapies.

Patients currently managing chronic spontaneous urticaria may want to discuss these cardiovascular risk findings with their physicians. This data provides additional context for comparing the safety profiles of available medication options.

The takeaway

Clinicians and patients should evaluate the long-term systemic effects of chronic urticaria treatments alongside immediate symptom relief. Understanding these cardiac correlations can lead to more personalized and safer long-term treatment plans.